
Home Page



Logo



URL

http://www.avac.org/media/news-digests

Subject

AIDS - Digest

Accessibility

Partially Free

Language

English

Publisher

AVAC: Global Advocacy for HIV Prevention

Brief History

In 1995, nine HIV treatment activists founded the AIDS Vaccine Advocacy Coalition, now AVAC, to speed the development of preventive HIV vaccines. Within a year, this small group published the first annual Industry Investment in HIV Vaccine Research report and incorporated as a non-profit organization. The weekly news digest's archive available on their website from 2014 onwards.

Scope and Coverage

The Weekly News Digest is a compilation of HIV prevention research media coverage and relevant science in peer-reviewed journals; material on other reproductive health issues; and matters of policy and politics relevant to HIV prevention research, development and advocacy. It covers HIV related various narrow topics like HIV vaccine, condom-male-female, HPV vaccines, lubricant, treatment, therapeutic vaccines etc.

Kind of Information

AVAC Digest provides different kinds of HIV related news, information, reports and so on. Entries are available with its title, abstract or short description, publication date. Also with each entry provides its primary source and its basic/main topic. An example is given below.

Reduction in HPV in young women in England following national immunization program

Each year around 2,000-2,500 women are diagnosed with cervical cancer in England, the most common cancer in women under 35. Infection with high-risk human papillomavirus (HR HPV) types 16 and 18 is responsible for around 70-80% of cervical cancers. A study conducted by Public Health England and presented at the Society for General Microbiology's Annual Conference shows a reduction in these two HR HPV types — which are included in the HPV vaccines used — in sexually active young women in England.

APRIL 18, 2014 | HPV Vaccines | Science Daily

Antiviral activity of genital tract secretions after oral topical tenofovir pre-exposure prophylaxis for HIV-1

Abstract

Background: Surrogate markers of HIV-1 pre-exposure prophylaxis and microbicide efficacy are needed. One potential surrogate is the antiviral activity in cervicovaginal lavage (CVL) after exposure to candidate products. We measured CVL antiviral activity in women using oral or vaginal tenofovir-based pre-exposure prophylaxis and correlated activity with drug and immune mediator levels.

APRIL 15, 2014 | PIEP | JAIDS

Special Features

- Contact and feedback option available with proper form.
- Links to social networking sites like Facebook, Twitter, Google+ and so on.
- ➤ One can subscribe newsletter through proper way.
- ➤ AVAC blog present. Recent blog post also available.
- New press release available in this site.

Arrangement Pattern

The article archives are arranged according to volume and issue wise under a particular year. Again within an issue entries are arranged according to publication date wise that is, newer to older order. An example is given below.

- 10 February 2017 VOLUME 18 ISSUE 6
- 3 February VOLUME 18 ISSUE 5
- 27 January 2017 VOLUME 18 ISSUE 4
- 20 January 2017 VOLUME 18 ISSUE 3
- 13 January 2017 VOLUME 18 ISSUE 2
- 6 January 2017 VOLUME 18 ISSUE 1
- 23 December 2016 VOLUME 17 ISSUE 51
- 16 December 2016 VOLUME 17 ISSUE 50 .

What will a President Trump mean for HIV patients?

But while HIV prevention may not be a priority for the Trump administration, a sudden outbreak is likely to disproportionately affect Trump voters who live in rural counties hit hard by the nation's opioid epidemic.

DECEMBER 15, 2016 The Week

HIV rate among gay Atlanta men as high as 1 in 2

Two recent studies show the staggering reach of HIV in metro Atlanta, documenting how the region leads other large urban areas in HIV diagnoses and how as many as 1 in 2 gay men in some counties are HIV-positive...Six US states exceeded the national average of MSM diagnosed with HIV in 2012—and all of them were in the South. Of the top 25 metros in terms of prevalence, 21 were south of the Ohio River.

DECEMBER 13, 2016 Project Q

Updated labeling for combo HIV drug Genvoya

The FDA has posted updated prescribing information for Genvoya, removing the warnings regarding bone loss and mineralization defects. Genvoya is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

DECEMBER 12, 2016 | Combination Prevention | EMPR

Remarks

Its purpose is to raise awareness around the range of opinions and information about HIV prevention research disseminated in the press and scientific journals and helps a neutral, objective basis decision-making and evidence-based advocacy.

Comparable Tools

- Open Medicine Digest (<u>https://blogs.biomedcentral.com/on-medicine/tag/open-medicine-digest/</u>)
- ➤ Medicine News Digest (http://www.medinewsdigest.com/)

Date of Access

May 08, 2017